Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2022 after the market close on Tuesday, August 9th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com/.
About Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions and regulatory agencies across 62 countries. Visit us at www.certara.com.
Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Daniel Yunger
Kekst CNC
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$16.73 |
| Daily Change: | 0.20 1.21 |
| Daily Volume: | 372,468 |
| Market Cap: | US$2.690B |
May 07, 2024 April 16, 2024 February 29, 2024 December 13, 2023 November 21, 2023 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
